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Herbal and dietary supplements (HDSs) incorporate 
a wide range of over-the-counter products including vi-
tamins, minerals, dietary elements, herbal preparations, 
and synthetic compounds. There are increasing reports of 
untoward HDS-related hepatotoxicity, with HDS products 
accounting for 20% of adults enrolled in the ongoing US 
Drug-Induced Liver Injury Network (DILIN) registry study.1,2 
In this article, we review the presenting features and out-
comes of severe acute hepatitis attributed to a commonly 
used multi-ingredient supplement, OxyELITE Pro (OEP), in-
cluding a previously reported exemplary case.3-7
Case
A 31-year-old Korean-American female presented with 
new-onset nausea, vomiting, and pruritus.3 The patient 
reported taking one tablet of OEP per day for the past 4 
months in an effort to lose weight associated with a recent 
full-term pregnancy. She was receiving no other medica-
tions, did not drink alcohol, and denied any recent sick 
contacts or travel. Her body mass index was 33.8 kg/m2; 
scleral icterus was present, but the remainder of her exam-
ination was unremarkable. Her initial serum aspartate ami-
notransferase was 710 IU/L, alanine aminotransferase (ALT) 
was 1972 U/L, alkaline phosphatase was 58 U/L, total 
bilirubin was 3.8 mg/dL, and international normalized ratio 
was 1.0. An evaluation for acute hepatitis A, B, C, and 
E, liver imaging, and anti-nuclear and anti–smooth muscle 
anti bodies were all negative. A liver biopsy obtained on hos-
pital day 5 showed severe acute hepatitis with cholestasis, 
apoptotic hepatocytes, and a periportal infiltrate with eo-
sinophils.3 The serum ALT and bilirubin levels normalized 
by day 38 of follow-up and remained normal thereafter 
(Fig. 1). The DILIN causality score was 1 (definite), and her 
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Roussel-Uclaf Causality Assessment Method (RUCAM) score 
was 7 (probable).
HDs Use in THe UniTeD sTaTes
HDS product use is substantial and increasing, with 
nearly 50% of adult Americans reporting use of an HDS 
product.8 HDS products are most commonly taken by non- 
Hispanic whites, women, and those older than 40 years 
with higher levels of education.8 The general public per-
ceives HDS products as being safer to take than conven-
tional medications because they are frequently derived 
from plants and other “natural” products, and are widely 
available in retail outlets without a prescription. However, 
HDS products require no evidence of safety nor efficacy 
testing prior to marketing per the Dietary Supplement 
Health and Education Act of 1994. In addition, manufactur-
ers are not required to follow good manufacturing process 
standards; therefore, HDS products are essentially regu-
lated as food products. Investigations of manufacturers are 
only undertaken when there are complaints of suspected 
adverse events or concern for possible contaminants or 
adulterants.
Use of HDS products is very common among athletes 
and other individuals attempting to lose weight or to stay 
physically fit. For example, recent data suggest that 69% 
of active duty military personnel use at least one HDS 
product, and 22% report using more than three per day.9 
The extensive use of these products is, in part, due to the 
marketing of such supplements to promote numerous 
health and performance benefits (e.g., enhanced energy 
and strength) and nonspecific “structure” and “function” 
claims.
PHenOTYPe OF OeP HePaTOTOXiCiTY
OEP is an HDS product that contains several herbal 
constituents, caffeine, yohimbine, and other ingredients, 
including the sympathomimetic drug 1,3-dimethylamyla-
mine (DMAA), in earlier formulations prior to 2013. The 
nature of OEP-induced liver injury was first brought to light 
when an outbreak of severe, acute hepatocellular injury 
with jaundice was reported in seven previously healthy 
military personnel taking OEP or a newer “Super Thermo” 
formulation of the product6 (Table 1). DMAA has been 
previously implicated in serious nonhepatic adverse events 
such as acute myocardial infarction.10 In March 2013, 
OEP products containing DMAA were removed from the 
marketplace by the manufacturer (USP Labs, Dallas, TX), 
and some had synthetic aegeline added to them. Aegeline 
is an alkaloid from the bael tree, Aegle marmelos, that 
has been used in Ayurvedic medicine for centuries. An 
epidemiological investigation by the US Food and Drug 
Administration (FDA) and Centers for Disease Control and 
Prevention (CDC) identified 36 cases of acute hepatitis 
associated with the use of various OEP formulations includ-
ing the Super Thermo formulation. In September 2013, 
FIG 1 Serum ALT and total bilirubin (T. bilirubin) levels in a 31-year-old Korean woman who experienced severe acute hepatocellular 
injury attributed to OEP.3 The improvement in total bilirubin levels lagged behind that of the serum ALT levels, but both had normalized 
by day 38 of follow-up.
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the manufacturer of OEP removed the formulations of OEP 
containing aegeline from the marketplace.4 A follow-up 
report from the CDC and other health authorities demon-
strated that the incidence of OEP hepatotoxicity markedly 
declined after 2014.5
The clinical features of OEP hepatotoxicity consisted of 
nausea and anorexia with a median peak serum ALT and 
total bilirubin values of 1740 U/L and 9.4 mg/dL, respec-
tively.5 Liver biopsies showed acute hepatitis suggestive of 
a toxic injury. One of the 44 patients died, and 2 others 
underwent emergency liver transplantation. Among the 
patients who recovered, many had a prolonged course 
with a few developing autoimmune hepatitis-like features 
managed with steroids.4 During the same time period, the 
DILIN database reported 7 cases of liver injury attributed 
to OEP following a median duration of use of 18 weeks 
(range: 5-102 weeks).3 All of the patients presented with 
an acute hepatocellular injury, leading to liver transplanta-
tion in two patients. Other cases have been reported from 
the continental United States and in active duty military 
personnel.6,7 Although there was an overrepresentation of 
Asian-Pacific islanders with OEP hepatotoxicity, confirma-
tory studies demonstrating a genetic or ethnic predisposi-
tion are lacking.
CaUsaliTY assessMenT in HDs 
HePaTOTOXiCiTY
Causality assessment in drug- and HDS-associated 
hepatotoxicity is complex and evolving due to the lack 
of a confirmatory, objective biomarker that is specific for 
DILI.2 Currently, most study groups use expert opinion or 
standardized instruments such as the RUCAM. Causality 
assessment methods take into consideration the temporal 
association between product intake and DILI onset, im-
provement with drug discontinuation, exclusion of com-
peting causes, and comparison of the laboratory, clinical, 
and histological phenotype of the case with what has pre-
viously been reported with that agent.11 Immunoallergic 
and autoimmune features are uncommon with most in-
stances of HDS hepatotoxicity, but latency is usually within 
6 months of exposure. Causality assessment in HDS cases 
is further confounded by the fact that many patients take 
more than a single HDS product simultaneously, and the 
specific chemical ingredients and blends of botanicals used 
in HDS preparations may vary substantially between lots 
and over time.2 A recent analysis from DILIN demonstrated 
a high level of discrepancy between the listed label ingredi-
ents of HDS products and those confirmed by using highly 
sensitive and specific liquid chromatography and mass 
spectroscopy methods.12
Analyses of OEP products looking for adulterants, 
known hepatotoxicants, and contaminants have failed to 
identify a known discrete hepatotoxin or unique ingredient 
in the lots of suspect product6,7 (Table 2). However, a re-
cent in vivo study demonstrated substantial hepatotoxicity 
and mortality in mice administered OEP-New formulation 
at 3 to 10 times the mouse equivalent dose, as well as in-
creased up-regulation of the Cd36 gene that is involved in 
lipid metabolism.13
In conclusion, clinicians should have heightened aware-
ness of the potential for inadvertent liver injury associated 
with the many HDS products that are used by millions of 
Americans on a daily basis. Reporting of adverse events 
to the FDA, the product manufacturer, and local health 
authorities is encouraged, as was done with the recent 
outbreak of OEP hepatitis, to improve patient outcomes 







DILI onset dates Prior to 2014 April to November 2013 August 2011 to December 2013
Location Southern California Hawaii Continental United States
Median age, years 24 33 36
Female sex, % 42 57 86
Asian/Pacific Islander, % Not reported 25* 43
Median peak ALT, U/L 1980 1740 2250
Median peak total bilirubin, mg/dL 6.7 9.4 13
Outcomes, %
Hospitalized 100 39 86
Liver transplant 28 5 28
Death 0 2 0
Concomitant HDS, % 42 68 71
*Fifty-seven percent were two or more races, including Asian, Pacific Islander, and/or Caucasian.
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and help identify unsafe products. In light of these findings, 
further regulations regarding the manufacturing, safety 
and efficacy testing, and monitoring of HDS products avail-
able in the marketplace are advisable and recommended.2
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TaBle 2. resUlTs OF OeP PrODUCT inGreDienT analYsis
OEP Super Thermogenic Capsules OEP Super Thermo Capsules OEP Super Thermo Powder
Availability Through July 2013 Late 2012 to October 2013 Through July 2013
Caffeine per serving 100 mg 135 mg 125 mg
Daily recommended amount 119.5 mg per serving 140 mg per serving 1058 mg per scoop
Proprietary blend Extract of Bauhinia purpurea leaf, Bacopa, 
Cirsium oligophyllum, yohimbine bark, 
DMAA
Extract of Bauhinia purpurea leaf, 
Hemerocallis fulva, yohimbine bark 
aegeline, norcoclaurine HCl
Extract of yohimbine bark, Eriobotrya 
japonica, aegeline, choline bitartrate, 
norcoclaurine HCl, l-carnitine-tartrate
Adapted from data presented by Johnston et al.5
